MedTrace Logo

Evaluation of the Hypoglycaemia Notification Device Hyposafe H02

NCT02925676 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-07-26

Study results available
· View outcomes & findings →

Summary

To evaluate the technical performance of the hyposafe H02 during everyday activities and during insulin-induced hypoglycaemia, in addition to safety issues associated with the implantation and use of the hyposafe H02 in subjects with type 1 diabetes.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DEVICE

hyposafe H02

hypoglycaemia notification device

Sponsors & Collaborators

  • UNEEG Medical A/S

    lead INDUSTRY

Principal Investigators

  • Ulrik Pedersen-Bjergaard, MD, PhD · Nordsjaellands Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-05
Primary Completion
2018-08-29
Completion
2018-09-10

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02925676 on ClinicalTrials.gov